Advanced Technology Corporation

Advanced Technology Corporation (ATC)
A.T.C. is a Contract Research Organisation (CRO) created in 1983 as a spin-off from the University of Liege and affiliated to the Academic Hospital of Liege since 2000. Since 1983, A.T.C. has been a provider of high-quality services in pre-clinical and clinical pharmacology for the Pharmaceutical Industry and Laboratories of Life Sciences. A.T.C. has a record of hundreds of successful in vitro and in vivo studies. The Laboratory involved in the project is the Pre-Clinical and Analytical (PCA) unit which has a long experience in

°       metabolic studies for the identification of drug metabolites and drug-metabolising enzymes
°       the prediction of drug-drug interactions,
°       the development and validation of methods for the determination of xenobiotics
°       their application within animal and human pharmacokinetic and toxicokinetic studies,
°       and studies of tissue distribution in animals, excretion balance and toxicity.

Since 1995, A.T.C. is GLP (good laboratory practice) certified by the Belgian authorities as defined by OECD. The PCA unit is equipped with state-of-the-art analytical laboratory tools, such as several liquid chromatography (LC) systems coupled with mass spectrometry or radioactive detection. Given the large experience of the PCA unit in the ADME (absorption, distribution, metabolism, excretion) strategy and the development of new drug entities, the contribution of A.T.C to FLUPHARM is essential.


PATRICE CHIAP | Pharm | MSc | PhD (2000)

Current position: General Manager of ATC and Responsible of the Pre-Clinical and Analytical Unit, Test Facility Manager, Study Director, Associate Professor at the University of Liege, Member of the Commission « Medicinal Chemistry » at the Belgian Pharmacopoeia. He is the person in charge of the administrative and financial aspects of the present project. All scientific work will be performed by ATC under his supervision.

Main techniques: Development of (bio)analytical methods, chemometrics (validation, transfer, experimental design), identification of the chemical structure of metabolites by mass spectrometry, management of a private company. He is also author and co-author of more than 80 peer-reviewed papers and is “reviewer” for several scientific journals.



Current position: Pre-Clinical Studies Manager and Study Director and responsible of pre-clinical studies.

Main techniques: He has significant experiences in supervision of pre-clinical in vitro and in vivo studies, development of new in vitro tests proposed by ATC (including cellular culture), pharmaco- and toxicokinetics, in vitro and in vivo toxicology within the framework of the REACH program.



Current position: Head of the Laboratory of Mass Spectrometry and Study Director and responsible of the Laboratory of Mass Spectrometry.

Main techniques: He has a large experience in mass spectrometry, in the development and validation of bioanalytical methods and their application in pharmaco- and toxicokinetic studies as well as in drug residue studies. He will also supervise the scientific work of the present project.